Skip to main content
. 2022 Jan 3;11:778774. doi: 10.3389/fonc.2021.778774

Table 3.

The adverse events in the endostar combined with chemotherapy.

Adverse Event Grade1 Grade 2 Grade 3 Grade 4 Total
myelosuppression 35 11 4 7 57 (57/221, 25.8%)
gastrointestinal reactions 53 1 1 0 55 (55/221, 24.9%)
allergies 9 1 1 0 11 (11/221, 5%)
pigmentation 14 7 0 0 21 (21/221, 9.5%)
abnormal liver function 46 5 0 0 51 (51/221, 23.1%)
arrhythmia 17 3 0 0 20 (20/221, 9%)
renal inadequacy 3 3 0 0 6 (6/221, 2.7%)
Total 177 31 6 7 221